Spruce Biosciences, Inc. (SPRB), Monday announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to the company's tralesinidase alfa enzyme replacement therapy or TA-ERT for the treatment of Sanfilippo Syndrome Type B, an ultra-rare, serious, and fatal genetic disease.The designation is backed by the integrated group-level clinical data, demonstrating a rapid, profound, and durable effect of TA-ERT in normalizing Cerebral Spinal Fluid Heparan Sulfate Non-Reducing En ...